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INTRODUCTION
Stroke is the third leading cause of morbidity and mortality in the United States. Cerebral ischemia is the largest category of stroke (1, 2) . Ischemic conditions cause impairment of brain energy metabolism and the release of excessive amounts of excitatory amino acids such as glutamate. Under the "excitotoxin hypothesis," high concentrations of glutamate activate calcium channels leading to an influx of calcium and eventual killing of certain populations of neurons in the central nervous system (3, 4) . Traditional treatments for ischemic stroke have focused on maintaining cardiac output, blood pressure and cerebral blood flow. More recently, attention has been devoted to developing new therapies directed at abnormal biochemical events at excitatory synapses (4-7).
Dextromethorphan (DM) has been generally used as an antitussive in the clinic. Both DM and its demethylated metabolite dextrorphan (DX) have also been found to be N-methyl-D-aspartate (NMDA) excitatory amino acid receptor antagonists, and antagonists of some calcium channels. A number of studies have demonstrated that DM and DX effectively attenuate both NMDA receptor-mediated neurotoxicity and hypoxic neuronal injury in cortical cell cultures and in cerebral ischemia animal models (8) (9) (10) (11) (12) . The central nervous system effects of DM and DX presuppose that these drugs are capable of crossing the blood-brain barrier (BBB). To date, however, the precise transport processes regulating passage of DM and DX through the BBB have not been described and have been presumed to be passive in nature.
In this study, we have investigated the cellular mechanisms regulating the uptake and passage of DM and DX across the BBB with primary cultures of brain microvessel endothelial cells (BMECs). Our findings are intended to form a basis for continued exploration into targeted delivery strategies for therapies directed at the treatment of stroke, cerebrovascular disease, and other neurological disorders.
METHODS
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Bovine BMECs were isolated from the gray matter scraped from cerebral cortices as previously detailed by Audus and Borchardt (13, 14) and Miller et al. (15) . In primary culture, these cells have been characterized biochemically and functionally as an appropriate in vitro model of the endothelial component of the BBB (13) (14) (15) (16) (17) .
For uptake studies, BMECs (50,000 cells/cm 2 ) were grown onto rat-tail collagen-coated and fibronectin-treated surfaces in 24-well tissue culture plates (18) . Confluent monolayers were formed in ten to fourteen days. To measure the uptake of [ Shi, F., Cavitt, J.L., Bailey, C., Malick, A.W., and Audus, K.L. (1993) Characterization of dextromethorphan and dextrorphan uptake by a putative glutamic acid carrier and passive diffusion across brain microvessel endothelium. Drug Delivery 1, 113-118. Publisher's official version: http://dx.doi.org/10.3109/10717549309022764. Open Access version: http://kuscholarworks.ku.edu/dspace/.
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Michaelis-Menten kinetic parameters (e.g., K m and V max ) were estimated from Lineweaver-Burke plots of the difference between 37ºC and 4ºC data. Half-maximal inhibition concentrations (IC 50 s) for the concentration-dependent effects of selected agents on either DM or DX uptake were estimated from routine nonlinear regression analysis of uptake data.
DM and DX Passage Across BMEC Monolayers
BMECs were grown onto rat-tail collagen-coated and fibronectin-treated polycarbonate membranes Apparent permeability coefficients were calculated using the formula: P = X / (A x t x C d ), where P was the apparent permeability coefficient (cm/sec), A was the diffusion area (0.636 cm Shi, F., Cavitt, J.L., Bailey, C., Malick, A.W., and Audus, K.L. (1993) Characterization of dextromethorphan and dextrorphan uptake by a putative glutamic acid carrier and passive diffusion across brain microvessel endothelium. Drug Delivery 1, 113-118. Publisher's official version: http://dx.doi.org/10.3109/10717549309022764. Open Access version: http://kuscholarworks.ku.edu/dspace/. 6 across the monolayers was calculated from the linearly regressed slope through linear data ( e.g., sampling times 1-70 minutes).
Statistics
All uptake and transport experiments were performed in replicates of three to ten different monolayers and data expressed in figures and tables as the mean ± standard deviation (SD). Data were tested for significant differences from untreated controls at the 0.05 level by using an analysis of various (ANOVA; Abstat Software, Ver. 7.01, Anderson-Bell Corp., Arvada, CO).
RESULTS
The BMEC uptake of either DM or DX was concentration-dependent, saturable, and temperature-dependent as shown in Figures 1 and 2 . The presence of rather significant cell association of the drugs at low temperature suggests significant cell binding, particularly for DX. In a series of fluorescence polarization experiments (data not shown), we were unable to demonstrate significant interactions of these drugs with BMEC membrane lipids labeled with diphenylhexatriene probes at 37ºC. Therefore, the cell associated drug at low temperature may have been surface binding of DX and DM.
Kinetic parameters for DM and DX uptake were estimated from Lineweaver-Burke plots of the difference between BMEC binding of drug at low temperature from the total binding and uptake of drug at 37ºC as shown in insets on Figures 1 and 2 , respectively. The V max s were similar and suggested the drugs were using the same uptake mechanism, but differed in affinity for that mechanism.
In a concentration dependent fashion, l-Glutamic acid, NMDA, and dl-threo-β-Hydroxyaspartic acid inhibited to some degree the uptake of [ Figures 3, 4 
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and 5. For both drugs, l-glutamic acid was the more efficient inhibitor of uptake based on estimated IC50s and as summarized in Table 1 . Glutathione inhibited uptake to a small degree but only at very high concentrations (>10 mM; not shown).
In contrast to the uptake process, passage of either DM or DX across BMEC monolayers was not saturable over a concentration range of 0.45 µM to 1 mM (not shown). DM crosses the monolayers at a faster rate than DX (p < 0.05). Apparent permeability coefficients for the bidirectional passage of DM and DX across the monolayers are listed in Table 2 . The corresponding transmonolayer fluxes exceeded the uptake V max s for the drugs (e.g., at 1 µM DM flux ~ 40 pmol/mg protein/min; at 1 µM DX flux ~ 28 pmol/mg protein/min). The difference between the rates of passage of DM from apical-to-basolateral versus basolateral-to-apical was not significant (p > 0.05). The difference between the rates of passage of DX from apical-to-basolateral versus basolateral-to-apical was also not significant (p > 0.05). Neither DM nor DX had a significant effect on the passage of an impermeant marker, fluorescein, across the BMEC monolayers relative to untreated control monolayers (p > 0.05; not shown) and confirmed the absence of possible adverse drug-induced effects on BMEC monolayer permeability.
Passage of DM and DX across the monolayers was not sensitive to 0.01 to 100 mM of selected agents, unlabeled DM, DX, l-glutamic acid or NMDA (not shown). A typical result for l-glutamic acid effects on DX passage across the BMEC monolayers is shown in Table 2 Table 2 .
DISCUSSION
Accumulating evidence suggests that a BBB uptake system for glutamic acid may assist in clearing the amino acid from the central nervous system. Oldendorf and Szabo (19) were the first to Shi, F., Cavitt, J.L., Bailey, C., Malick, A.W., and Audus, K.L. (1993) Characterization of dextromethorphan and dextrorphan uptake by a putative glutamic acid carrier and passive diffusion across brain microvessel endothelium. Drug Delivery 1, 113-118. Publisher's official version: http://dx.doi.org/10.3109/10717549309022764. Open Access version: http://kuscholarworks.ku.edu/dspace/. 8 observe the uptake of glutamic acid and aspartic acid at the BBB. The estimated K m for glutamic acid uptake at the BBB (20) is at least four times lower than the typical plasma concentration. Consequently, the BBB carrier is normally saturated and does not permit systemic glutamic acid to enter the brain compartment even when systemic concentrations are substantially elevated. The uptake system has been postulated to be part of a protective unidirectional efflux system that provides for the transport of glutamic acid from the brain (20) . More recently, Koenig et al. (21) characterized a high affinity NMDA subclass of glutamic acid binding sites on the apical or luminal surface of BBB endothelia. In this latter study, too, the researchers provided evidence that these binding sites may play a role in regulating BBB transport processes.
The mechanism by which DM and DX cross the BBB has been assumed to be passive and has not been extensively investigated either in vivo or in vitro. Although it is clear that these drugs interact with glutamic acid binding sites (5, 6) , affinity for the amino acid's uptake mechanism has not been investigated. In this study, we have shown that both DM and DX were taken up by BMECs through a saturable and temperature-sensitive system. Several observations here suggest that DM and DX may be interacting with a glutamic acid uptake carrier. First, of those substances tested in this study, glutamic acid was found to be the more effective and complete inhibitor of the BMEC uptake of either DM or DX.
Other agents expected to interact with glutamic acid type binding sites, NMDA and DL-threo-β-hydroxyaspartate also significantly inhibited DM and DX uptake. The glutamic acid carrier has been described as having one of the lowest transport capacities among the nutrient carriers of the BBB (19, 20) . The V max s for DM and DX were substantially lower than observed for biotin (18) and leucine (22) carriers in BMEC monolayers and would be consistent with such a low capacity uptake mechanism. The K m for glutamic acid uptake at the BBB in vivo has not been directly determined, however, Pardridge (20) estimated the apparent K m from Oldendorf and Szabo's original work (19) to be about 0.04 mM. While the K m s for DM and DX for the carrier system in this study were higher, it is likely that they were within Shi 
9 the range one might expect for alternative substrates for the carrier. Finally, the sub-mM concentrations used in this study were consistent with the in vitro pharmacological activity of the drugs in modulating glutamic acid toxicity. DM and DX concentrations of 0.01 to 0.10 mM, for example, inhibit 0.50 mM glutamic acid-induced neurotoxicity in vitro (9) . Additionally, DX concentrations of 0.001 to 0.01 mM protect neuronal cell cultures against extracellular acidity (23) .
There is at least one other potential carrier known at the BBB for glutamyl-like compounds, a specific and saturable glutathione transcellular transporter (24, 25) . The glutathione carrier has been described as highly specific, failing, for instance, to recognize either glutathione degradation products or individual amino acids (24, 25) . In our studies, glutathione was without substantial effects on the BMEC uptake of either DM or DX above the apparent K m of ÷ 6.0 mM for the glutathione transporter. Thus far, our results are in agreement with the presence of a separate, high affinity, low capacity glutamic acid uptake carrier and suggest that DM and DX may be recognized by a putative glutamic acid uptake system.
Generally, passage of DM and DX across the BBB in vivo has been assumed to be by a passive mechanism. Consistent with that assumption and unlike other agents studied, i.e., biotin (18) and leucine (22) , the bidirectional passage of DM and DX across BMEC monolayers was neither saturable nor inhibited by structurally-related agents. The permeation of DM across BMEC monolayers was not substantially altered by pretreatment with the metabolic poison, 2-deoxyglucose, suggesting the absence of any energy-dependence for transmonolayer passage. Since 2-deoxyglucose has been found to reduce passage through the paracellular route for impermeable paracellular markers such as fluorescein and fluorescein-conjugated dextrans (26) , results here would also suggest that DM follows a transcellular pathway across the BMEC monolayers. On the other hand, DX passage across the monolayers was reduced by 2-deoxy-D-glucose to a significant degree but not to the extent of fluorescein (26) . Based on this observation DX probably utilizes both a transcellular route and any Shi, F., Cavitt, J.L., Bailey, C., Malick, A.W., and Audus, K.L. (1993) Characterization of dextromethorphan and dextrorphan uptake by a putative glutamic acid carrier and passive diffusion across brain microvessel endothelium. Drug Delivery 1, 113-118. Publisher's official version: http://dx.doi.org/10.3109/10717549309022764. Open Access version: http://kuscholarworks.ku.edu/dspace/. 10 paracellular paths that might be available in this in vitro system. Evidence in support of a transcellular route also includes the observation that the fluxes of both DM and DX exceeded the flux of the paracellular marker, fluorescein, across the BMEC monolayers.
In other studies with the BMEC monolayers, we found that for transported substrates such as biotin, the uptake Vmax was within ten-fold of the apparent transmonolayer flux. Differences between the rates could be accounted for by the assymmetrical nature of biotin transfer across the BMECs (18) .
By contrast, the rates of diffusion of DM and DX across the BMEC monolayers far exceeded the corresponding Vmaxs for apical BMEC uptake and were not significantly different from respective basolateral-to-apical fluxes. Given the absence of factors suggestive of a transcellular carrier mechanism, the large difference between flux and uptake would seem to suggest that the uptake mechanism would play a minor role in the overall transcellular passage of DM and DX.
The rate of DM passage across the BMEC monolayers was significantly greater than DX, perhaps not unlike the situation for their l-analogs. In the heroin-morphine model, masking of hydroxyl groups on morphine with either one acetyl group (i.e., codeine) or two acetyl groups (i.e., heroin) allows enhanced passive permeation across the BBB (27) . The removal of the single methyl group from DM to form DX also seems to have limited the availability for transcellular passage and in the process enhanced BMEC binding. It is worth noting that apparent differences in BBB permeability are not necessarily reflective of the pharmacological activity. Despite a lower BBB permeability, morphine is considered the active form of heroin. Similarly, the de-methylated DX is more potent than DM as an anticonvulsant in vivo (5).
In summary, we have provided evidence that DM and DX were taken up on the apical surface of BMECs through a saturable, low capacity carrier mechanism. We suggest that this mechanism may be the glutamic acid uptake carrier of the BBB. Although confirmatory studies are necessary, this observation would suggest that DM and DX could potentially target and modulate the uptake and Shi, F., Cavitt, J.L., Bailey, C., Malick, A.W., and Audus, K.L. (1993) Characterization of dextromethorphan and dextrorphan uptake by a putative glutamic acid carrier and passive diffusion across brain microvessel endothelium. Drug Delivery 1, 113-118. Publisher's official version: http://dx.doi.org/10.3109/10717549309022764. Open Access version: http://kuscholarworks.ku.edu/dspace/. 11 biological effects of glutamic acid in the cerebrovasculature. Our results also support the hypothesis that net passage of DM and DX across the blood-brain barrier occurs by a mechanism that is dependent on the physicochemical properties of the individual drugs (i.e., relative lipophilicities) and therefore, passive in nature. 
